News

Patient Cole Villaflor, his mother, and Michael Levy, MD, PhD, provide insights into Cole’s hyperhidrosis diagnosis and subsequent endoscopic thoracic sympathectomy surgery.

From the November cover: Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls into atopic dermatitis management for adults and children.

Experts discuss enhancing patient outcomes, topical formulations and epidermal barrier dysfunction, and more.

The newest source of growth factors is from donor tissue.

Immunotherapies, including PD-1 checkpoint inhibitors such as nivolumab, have improved the treatment options for patients with advanced melanoma.

Atoosa Kourosh, MD, MPH, delves into opportunities for allergists and dermatologists to collaborate, her approach to cases, and patient resources.

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.

This week’s collection of the latest dermatologic studies covers the relationship between melanoma pigmentation and inflammatory cytokines, the negative use of topical nystatin for tinea infections, the association between psoriasis and schizophrenia, and the association between pediatric atopic dermatitis and cardiovascular risk factors.

Keep up with the latest headlines in dermatology from the past week, including research revealing the presence of hemoglobin in the epidermis, 3D bioprinting to create hair follicles in human skin tissue, and more.

ICYMI, this week we had articles about coverage from the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting, the availability of UCB's bimekizumab, FDA breakthrough therapy designation to QTORIN rapamycin for microcystic lymphatic malformations, and more.

Kwatra presented on the unmet need for itch improvement in patients with skin of color.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, discusses Apex Dermatology's Purple Heart Project.

Germany will be the first country where lebrikizumab will be available for prescription, with a subsequent rollout across European countries throughout 2024.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

November is Native American Heritage Month. Access to dermatological health care has been a persistent challenge for individuals in the AIAN community.

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.

Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the US and is projected to maintain a substantial market lead over ritlecitinib.

Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.

There are currently no FDA-approved therapies for the rare, genetic disease.

Experts Heather Woolery-Lloyd, MD; Chesahna Kindred, MD, MBA, FAAD; Gary M. Owens, MD; and Renata Block, MMS, PA-C, discuss the evolving landscape of vitiligo, particularly from an economic lens.

The partnership will combine dermatological expertise and Absci's Integrated Drug Creation platform.

This week’s collection of the latest dermatologic studies covers atypical molluscum contagiosum lesions with a CD30-positive T-cell lymphoid infiltrate, comorbidities in pediatric psoriasis, tralokinumab for adolescents with severe AD, and intralesional bleomycin combined with lidocaine for recalcitrant keloid scars.

Dermatology Times, the SDPA, and more are celebrating the invaluable contributions of nurse practitioners in dermatology this NP Week (November 12-18).

Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.

Experts discuss insights and hot topics stemming from this year's Science of Skincare Summit, including upcoming innovations and considerations in dermatology.

In honor of National Healthy Skin Month, it is the perfect time to encourage patients to integrate gentle laser treatments into their yearly routine to maintain healthy, radiant skin.

Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.

In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.

Dermatology encompasses cosmetics, unregulated products, OTC drugs, OTC devices, prescription devices, and prescription drugs, whether oral, injectable, or topical.

2023 has been complete with numerous innovations in the dermatology space, including in atopic dermatitis, psoriasis, alopecia areata, and more.